Regeneron Pharmaceuticals, Inc. $REGN Stock Holdings Trimmed by Sumitomo Life Insurance Co.

Sumitomo Life Insurance Co. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 64.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 824 shares of the biopharmaceutical company’s stock after selling 1,496 shares during the quarter. Sumitomo Life Insurance Co.’s holdings in Regeneron Pharmaceuticals were worth $433,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Activest Wealth Management grew its holdings in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 21 shares during the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $27,000. Colonial Trust Advisors bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $32,000. Finally, SouthState Corp grew its holdings in shares of Regeneron Pharmaceuticals by 550.0% during the first quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 44 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 7.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on REGN. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Wells Fargo & Company increased their price objective on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 29th. Finally, Jefferies Financial Group increased their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $802.36.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $642.25 on Tuesday. The company has a market capitalization of $68.07 billion, a price-to-earnings ratio of 15.38, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $852.01. The business has a 50 day moving average price of $583.20 and a two-hundred day moving average price of $565.94.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the firm posted $12.46 earnings per share. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.